查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1959197

全球糖尿病前期市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Prediabetes Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 114 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計糖尿病前期市場將從 2025 年的 2.5937 億美元成長到 2034 年的 5.0693 億美元，2026 年至 2034 年的複合年成長率為 7.73%。

全球糖尿病前期市場預計將迎來顯著成長，這主要得益於糖尿病前期盛行率的不斷上升以及人們對糖尿病前期健康影響的認知不斷提高。糖尿病前期是一種血糖值升高但尚未達到糖尿病診斷標準的疾病，影響著全球數百萬人口。隨著醫療服務提供者和患者逐漸認知到早期療育對於預防第2型糖尿病發展的重要性，對糖尿病前期篩檢、診斷工具和管理解決方案的需求預計將大幅成長，從而推動這一關鍵市場的創新和投資。

此外，數位健康技術和個人化醫療的進步預計將進​​一步推動糖尿病前期市場的發展。行動醫療應用、穿戴式裝置和遠距醫療平台的開發將使人們能夠監測血糖值、追蹤生活方式的改變，並獲得醫療專業人員的個人化指導。此外，隨著人們越來越重視包括飲食改善和體能活動在內的生活方式改善計劃，對能夠幫助個人主導自身健康的綜合管理解決方案的需求也日益成長。隨著醫療保健格局的不斷演變，預計糖尿病前期解決方案市場將迎來對滿足多樣化患者需求的創新產品和服務的激增。

此外，對監管合規和公共衛生舉措日益重視預計將塑造糖尿病前期市場的未來。隨著各國政府和醫療機構實施旨在提高公眾意識和推廣預防措施的項目，對糖尿病前期篩檢和管理解決方案的需求將持續成長。醫療服務提供者、技術開發商和監管機構之間的合作對於推動這些發展並確保糖尿病前期市場能夠持續滿足患者和醫療系統不斷變化的需求至關重要。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場問題
  • 波特五力分析
  • PESTLE分析

第4章：全球糖尿病前期市場：依藥物類別分類

  • 市場分析、洞察與預測
  • 甲胍
  • 胰島素增敏劑
  • Glucagon-Like Peptide-1促效劑（GLP-1）
  • SGLT2抑制劑
  • DPP-4抑制劑
  • 其他

第5章：全球糖尿病前期市場：依年齡層別分類

  • 市場分析、洞察與預測
  • 兒童（12-18歲）
  • 成年人（18-49歲）
  • 老年人（50歲以上）

第6章 全球糖尿病前期市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Novo Nordisk
    • Valbiotis
    • Resverlogix
    • Caelus Health
    • SciMar
    • Boston Therapeutics
    • Aphaia Pharma
    • AstraZeneca
    • Bristol-Myers Squibb
簡介目錄
Product Code: VMR112114025

The Prediabetes Market size is expected to reach USD 506.93 Million in 2034 from USD 259.37 Million (2025) growing at a CAGR of 7.73% during 2026-2034.

The global prediabetes market is poised for significant growth, driven by the increasing prevalence of prediabetes and the rising awareness of its health implications. Prediabetes, characterized by elevated blood sugar levels that are not yet high enough to be classified as diabetes, affects millions of individuals worldwide. As healthcare providers and patients recognize the importance of early intervention to prevent the progression to type 2 diabetes, the demand for screening, diagnostic tools, and management solutions for prediabetes is expected to rise substantially, fostering innovation and investment in this critical market.

Moreover, advancements in digital health technologies and personalized medicine are anticipated to further boost the prediabetes market. The development of mobile health applications, wearable devices, and telehealth platforms enables individuals to monitor their blood sugar levels, track lifestyle changes, and receive personalized guidance from healthcare professionals. Additionally, the growing emphasis on lifestyle modification programs, including dietary changes and physical activity, is driving the demand for comprehensive management solutions that empower individuals to take control of their health. As the healthcare landscape continues to evolve, the market for prediabetes solutions is likely to witness a surge in demand for innovative products and services that cater to diverse patient needs.

In addition, the increasing focus on regulatory compliance and public health initiatives is expected to shape the future of the prediabetes market. As governments and health organizations implement programs aimed at raising awareness and promoting preventive measures, the demand for prediabetes screening and management solutions will continue to rise. Collaborative efforts between healthcare providers, technology developers, and regulatory bodies will be essential in driving these advancements, ensuring that the prediabetes market remains responsive to the evolving needs of patients and healthcare systems.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

  • Biguanide
  • Thiazolidinediones
  • Glucagon-Like Peptide-1 Agonists (GLP-1)
  • SGLT2 Inhibitors
  • DPP-4 Inhibitors
  • Others

By Age Group

  • Children (12-18 Years)
  • Adults (18-49)
  • Elderly (50+)

COMPANIES PROFILED

  • Novo Nordisk, Valbiotis, Resverlogix, Caelus Health, SciMar, Boston Therapeutics, Aphaia Pharma, AstraZeneca, BristolMyers Squibb

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PREDIABETES MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Biguanide Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Thiazolidinediones Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Glucagon-Like Peptide-1 Agonists (GLP-1) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. SGLT2 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. DPP-4 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PREDIABETES MARKET: BY AGE GROUP 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Age Group
  • 5.2. Children (12-18 Years) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Adults (18-49) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Elderly (50+) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PREDIABETES MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Drug Class
    • 6.2.2 By Age Group
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Drug Class
    • 6.3.2 By Age Group
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Drug Class
    • 6.4.2 By Age Group
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Drug Class
    • 6.5.2 By Age Group
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Drug Class
    • 6.6.2 By Age Group
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PREDIABETES INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Novo Nordisk
    • 8.2.2 Valbiotis
    • 8.2.3 Resverlogix
    • 8.2.4 Caelus Health
    • 8.2.5 SciMar
    • 8.2.6 Boston Therapeutics
    • 8.2.7 Aphaia Pharma
    • 8.2.8 AstraZeneca
    • 8.2.9 Bristol-Myers Squibb